



Urovant Sciences to Report Second Fiscal Quarter 2020 Financial Results

October 27, 2020

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Oct. 27, 2020-- Urovant Sciences (Nasdaq: UROV) announced today that it will report financial results for its fiscal quarter ended September 30, 2020 after the close of U.S. financial markets on Monday, November 2, 2020.

Management will host a conference call to discuss Urovant's financial results at 1:30 p.m. Pacific / 4:30 p.m. Eastern that same day. A question and answer session will follow management's remarks.

The conference call numbers are (866) 470-1049 for domestic callers and (409) 217-8245 for international callers. The conference ID is 8054049.

A replay of the call will be available approximately four hours after the call and will be accessible for 7 days at (855) 859-2056, conference ID 8054049. A webcast will be archived on the Investor Relations page of the Urovant Sciences website immediately after the call and will be available for 30 days.

About Urovant Sciences

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. The Company's lead product candidate, vibegron, is an oral, once-daily small molecule beta-3 agonist that is being evaluated for overactive bladder (OAB). Urovant Sciences reported positive data from the vibegron 12-week, phase 3 pivotal EMPOWUR study and demonstrated favorable longer-term efficacy, safety, and tolerability in a 40-week extension study. The Company submitted a New Drug Application to the FDA seeking approval of vibegron for the treatment of patients with OAB in December 2019. Vibegron is also being evaluated for treatment of OAB in men with benign prostatic hyperplasia (OAB+BPH) and for abdominal pain associated with irritable bowel syndrome (IBS). Urovant's second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy. Urovant Sciences, a subsidiary of Sumitomo Dainippon Pharma Co., Ltd., intends to develop novel treatments for additional urologic diseases. Learn more about us at www.urovant.com.

About Sumitovant Biopharma Ltd.

Sumitovant is a global biopharmaceutical company with offices in New York City and London. Sumitovant is a wholly owned subsidiary of Sumitomo Dainippon Pharma. Sumitovant is the majority shareholder of Urovant and Myovant, and wholly owns Enzyvant, Spirovant, and Altavant. Sumitovant's promising pipeline is comprised of early-through-late-stage investigational medicines across a range of disease areas targeting high unmet need. For further information about Sumitovant, please visit <https://www.sumitovant.com>.

About Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma is among the top-ten listed pharmaceutical companies in Japan, operating globally in major pharmaceutical markets, including Japan, the U.S., China, and the European Union. Sumitomo Dainippon Pharma is based on the 2005 merger between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than 6,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at <https://www.ds-pharma.com>.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20201027005352/en/): <https://www.businesswire.com/news/home/20201027005352/en/>

Investor and Media Inquiries:

Ryan Kubota
949.769.2706
ryan.kubota@urovant.com

Source: Urovant Sciences